Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study

    Research output: Contribution to journalLetterResearchpeer-review

  2. A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. ECCO topical review: Refractory Inflammatory Bowel Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The burden of inflammatory bowel disease in Europe in 2020

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND AND AIMS: Patients with inflammatory bowel diseases (IBDs) are at risk of developing a variety of other immune-mediated inflammatory diseases (IMIDs). The influence of co-occurring IMIDs on the disease course of IBD remains unknown. The aim of this study was therefore to conduct a systematic review and meta-analysis of the impact of IMIDs on phenotypic presentation and outcome in patients with IBD.

METHODS: PubMed and Embase were searched from their earliest records through December 2018 and updated in October 2019 for studies reporting proportions or ratios of IBD-related disease outcomes in patients with and without co-occurring IMIDs. Meta-analyses were performed to estimate summary proportions and risks of the main outcomes. PRISMA guidelines were used, and study quality was assessed according to the Newcastle-Ottawa Scale.

RESULTS: A total of 93 studies were identified, comprising 16,064 IBD patients with co-occurring IMIDs and 3,451,414 IBD patients without IMIDs. Patients with IBD and co-occurring IMIDs were at increased risk of having extensive colitis or pancolitis (risk ratio, 1.38; 95% Cl, 1.25-1.52; P < 0.01, I2 = 86%) and receiving IBD-related surgeries (risk ratio, 1.17; 95% Cl, 1.01-1.36; P = 0.03; I2 = 85%) compared with patients without IMIDs. Co-occurrence of IMIDs other than primary sclerosing cholangitis in patients with IBD was associated with an increased risk of receiving immunomodulators (risk ratio, 1.15; 95% Cl, 1.06-1.24; P < 0.01; I2 = 60%) and biologic therapies (risk ratio, 1.19; 95% Cl, 1.08-1.32; P < 0.01; I2 = 53%).

CONCLUSION: This meta-analysis found that the presence of co-occurring IMIDs influences the disease course of IBD, including an increased risk of surgery and its phenotypical expression.

Original languageEnglish
JournalInflammatory Bowel Diseases
Publication statusPublished - 2020

ID: 60308169